What does this preliminary diagnosis for lung cancer indicate?
PET/CT SKULL BASE TO THIGHS:
1. Large lobulated mass projecting at the superior segment of the right lower lobe with increased metabolic activity compatible with neoplastic process. This confirms the CT chest finding.
2. A 1.5 x 2 x 1.5 cm lymph node at the subcarinal space. There is no increased metabolic activity to indicate active disease. Scattered prevascular lymph nodes as well as anterior superior mediastinum without significant increased metabolic activity.
3. Soft tissue mass with heterogeneous attenuation as well as calcification projecting inferior to the left lobe of thyroid gland with mild increased metabolic activity. Substernal goiter is the first consideration. A lymph node is a possibility.
3. Small right renal cyst.
4. Thickening of the urinary bladder wall without focal mass likely associated with previous inflammatory or infectious process.
END OF IMPRESSION:
INDICATION: A 62-year-old male patient with history of pulmonary mass as well as mediastinal mass for diagnosis.
TECHNIQUE: Following intravenous administration of 15.86 mCi of F-18 FDG, PET scan was obtained from skull base to mid thigh after a 55 minute waiting period. Low dose CT scan was also obtained for soft tissue attention and anatomic localization.
Blood glucose prior to injection was 96 MG/dL before examination.
INJECTION SITE: Right antecubital fossa.
COMPARISON: Correlation is made with a CT of the chest dated 8/7/2015.
Mediastinal Blood pool: 2.37 SUV.
Normal Lung parenchyma: 1.31 SUV.
Normal Hepatic parenchyma: 3.08 SUV.
SKULL BASE AND NECK:
There is normal oral, pharyngeal and laryngeal uptake. No metabolically active masses or adenopathy are identified.
There is a large lobulated mass projecting at the superior segment of right lower lobe, measuring approximately 6.2 x 4.5 x 5.5 cm. There is increased metabolic activity with a maximum SUV of 12.6 on the early and 16.1 on the delayed images. This confirms the previous CT chest finding. Respiratory motion artifact with diffuse ground-glass opacity of the lung parenchyma. Bibasilar dependent atelectasis. Scattered blebs and bulla.
There is a 1.5 x 2 x 1.5 cm lymph node at the subcarinal space. No increased metabolic activity is identified. There are other scattered lymph nodes at the prevascular space and anterior mediastinum, largest of which measures approximately 1.2 cm. No increased metabolic activity is identified to indicate active disease. There is a soft tissue mass with heterogeneous attenuation and calcification measuring approximately 5 x 3.8 x 4.7 cm projecting inferior to the left lobe of the thyroid gland likely associated with substernal goiter. There is mild increased metabolic activity with a maximum SUV of 2.5 seen only on the delayed images.
ABDOMEN AND PELVIS:
There is normal mild heterogenous distribution in the liver and spleen. The gallbladder is normally visualized on CT. The pancreas and adrenal glands are unremarkable both on PET and CT. There is a small right renal cyst. The left kidney is normal. No significant adenopathy is evident on PET or CT. There is thickening of the urinary bladder wall without focal mass. There is normal GI and GU tract uptake.
MUSCULOSKELETAL: Scattered tiny osteophytes. Bilateral lower facet joint arthritis. No blastic or lytic lesion is identified. There is no increased metabolic activity to indicate skeletal metastasis.
The following criteria are included to assist the referring physician with evaluation of PET CT Response to Solid Organ Tumors if needed.
EORTC Response Criteria.
European Organization for Research and Treatment of Cancer.
CMR (Complete Metabolic Response) : Complete resolution of FDG uptake within the tumor volume.
PR (Partial Metabolic Response): A reduction of a minimum of 15-25% in tumor FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle.
PMD (Progressive Metabolic Disease): Increase FDG tumor SUV of greater than 25% within the tumor region, or increase of extend of FDG uptake (20% in longest dimension) or appearance of new lesions.
SMD (Stable Metabolic Disease): Increase of less than 25% or a decrease of less than 15% in tumor FDG SUV and no visible increase in extent (20% in longest dimension)
Response Evaluation Criteria in Solid Tumors
CR (complete response) = disappearance of all target lesions
PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions
PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions
SD (stable disease) = small changes that do not meet above criteria
The following Deauville criteria will applied to ALL Hodgkin's Lymphoma or Aggressive non-Hodgkin's Lymphoma patients who are within the interim following a few cycles of chemotherapy (who possess a baseline PET- CT prior to therapy) ONLY:
1 = No Uptake
2 = Uptake is < Mediastinum
3 = Uptake is > Mediastinum but = Liver
4 = Uptake is > than Liver at any site
5 = Uptake is > Liver and new sites of disease
A score of 1-3 are considered NEGATIVE (indicating appropriate response to chemotherapy)
A score of 4 or 5 is considered POSITIVE (indicating lack of response to chemotherapy)
He is having stage 2 lung cancer.
Thanks for your question on Health Care Magic.
I can understand your concern.
I have gone through the report.
PET scan is indicated to identify the metastatic lesions in distal organ.
He is having lung mass in right lower lobe.
Lung cancer commonly spreads to liver, bones, brain, intestine etc. And if any of these organs is involved than it is considered as stage 4 cancer. But in his case, distal metastases are absent and so he is not having stage 4 disease.
Size of tumour is less than 7 cm. So he is mostly having stage 2 cancer. And it is operable cancer.
But first determine the type of lung cancer.
Lung cancer is broadly decided in two types.
1. Small cell lung cancer (SCLC)
2. Non small cell lung cancer (NSCLC).
SCLC I having poor prognosis. While NSCLC is more common and have good prognosis if early surgery is done.
So he needs biopsy to determine type of lung cancer. And on its result, treatment will be guided.
Hope I have solved your query.
I will be happy to help you further.
Wishing good health to your brother. Thanks.
The User accepted the expert's answer
Get personalised answers from verified doctor in minutes across 80+ specialties
- Diagnosis of groin lung cancer
- Diagnosis of advanced lung cancer
- Diagnosis of terminal lung cancer
- Diagnosis of relapsed lung cancer
- Diagnosis of Lung cancer
- Diagnosis of asymptomatic lung cancer
- Diagnosis of primary lung cancers
- Diagnosis of secondary lung cancer
- Diagnosis of neuroendocrine lung cancer
- Diagnosis of metastatic lung cancer
- How can severe COPD be handled when it has worsened after quitting smoking?
- What causes chronic cough?
- Suggest treatment for interstitial lung disease
- Suggest treatment for bronchiectasis
- Suggest treatment for anxiety and sleeping problems
- What causes dizziness after eating red meat?
- How to avoid insomnia caused by Albuterol taken for COPD treatment?
- What causes prolonged fever?
- Suggest treatment for clogged ears and inflamation in sinus passage
- What causes white foamy sputum when suffering from COPD?